Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT04023110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04023110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2019
Completion date
January 14, 2025
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cardiomyopathies, cardiotoxicity, heart failure, risk factor, cardiovascular, toxicity due to chemotherapy